» Articles » PMID: 36287462

A Guideline for Economic Evaluations of Vaccines and Immunization Programs in China

Abstract

This study aimed to develop a consensus framework for economic evaluations of vaccines as a national guideline in China. Some unique and important aspects were particularly emphasized. Nineteen Chinese experts in the field of health economics and immunization decision-making were nominated to select and discuss relevant aspects of vaccine economic evaluations in China. A workshop attended by external experts was held to summarize unique and important aspects and formulate consensus recommendations. There were ten unique and/or important aspects identified for economic evaluations of vaccines in China, including study perspectives, comparator strategies, analysis types, model choices, costing approaches, utility measures, discounting, uncertainty, equity, and evaluation purposes. Background information and expert recommendations were provided for each aspect. Economic evaluations of vaccines should play an important role in China's immunization policy-making. This guideline can help improve the quality of economic evaluations as a good practice consensus.

Citing Articles

Cost-based COVID-19 vaccination and willingness to pay: A post-pandemic review.

Wong L, Lee H, Alias H, Zimet G, Liu T, Lin Y Hum Vaccin Immunother. 2024; 20(1):2313860.

PMID: 38359815 PMC: 10877984. DOI: 10.1080/21645515.2024.2313860.


Vaccine pricing strategies in China.

Zhang H, Patenaude B, Ma C, Fang H BMJ Glob Health. 2023; 8(7).

PMID: 37402511 PMC: 10335538. DOI: 10.1136/bmjgh-2022-011405.

References
1.
Song X, Zhao Q, Zhou Z, Fang Y . [Health economic evaluation of bivalent human papilloma virus vaccine in China: based on the dynamic model]. Zhonghua Yu Fang Yi Xue Za Zhi. 2017; 51(9):814-820. DOI: 10.3760/cma.j.issn.0253-9624.2017.09.008. View

2.
Mauskopf J, Standaert B, Connolly M, Culyer A, Garrison L, Hutubessy R . Economic Analysis of Vaccination Programs: An ISPOR Good Practices for Outcomes Research Task Force Report. Value Health. 2018; 21(10):1133-1149. DOI: 10.1016/j.jval.2018.08.005. View

3.
Mo X, Tobe R, Wang L, Liu X, Wu B, Luo H . Cost-effectiveness analysis of different types of human papillomavirus vaccination combined with a cervical cancer screening program in mainland China. BMC Infect Dis. 2017; 17(1):502. PMC: 5516327. DOI: 10.1186/s12879-017-2592-5. View

4.
Zhao D, Tobe R, Cui M, He J, Wu B . Cost-effectiveness of a 23-valent pneumococcal polysaccharide vaccine immunization programme for the elderly in Shanghai, China. Vaccine. 2016; 34(50):6158-6165. DOI: 10.1016/j.vaccine.2016.11.003. View

5.
Wang J, Zhang H, Zhang H, Fang H . Public health impact and cost-effectiveness of rotavirus vaccination in China: Comparison between private market provision and national immunization programs. Hum Vaccin Immunother. 2022; 18(7):2090162. PMC: 10019831. DOI: 10.1080/21645515.2022.2090162. View